BCR and lymphoma: Pre-clinically, the activation of BCR signaling was associated with anti-lymphoma activity of bimiralisib and activity against lymphoma cell lines was observed in combination with other targeted therapies, including rituximab, ibrutinib, lenalidomide, ARV-825, marizomib, venetoclax, and panobinostat [39].